Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.
复制标题

DOI:
10.1186/1756-8722-4-13
复制
发表时间:
2011-04-01
影响因子:
28.5
通讯作者:
Takahashi S
Takahashi S
中科院分区:
医学1区
文献类型:
--
作者:
Takahashi S

文献摘要

参考文献

被引文献

相似文献

FLT3是一种III型受体酪氨酸激酶。FLT3突变是急性髓系白血病中最常被识别的基因改变类型之一。三分之一的急性髓系白血病患者存在该基因的突变,并且这些突变中的大多数涉及FLT3近膜区的内部串联重复,导致下游信号通路的持续性激活和细胞异常生长。这篇综述总结了目前对FLT3激活后下游分子信号通路影响的理解,尤其关注对转录因子的影响。此外,该综述还描述了新型的针对FLT3的治疗方法,以及针对FLT3突变白血病细胞的有效联合疗法。
FLT3 is a type III receptor tyrosine kinase. Mutations of FLT3 comprise one of the most frequently identified types of genetic alterations in acute myeloid leukemia. One-third of acute myeloid leukemia patients have mutations of this gene, and the majority of these mutations involve an internal tandem duplication in the juxtamembrane region of FLT3, leading to constitutive activation of downstream signaling pathways and aberrant cell growth. This review summarizes the current understanding of the effects of the downstream molecular signaling pathways after FLT3 activation, with a particular focus on the effects on transcription factors. Moreover, this review describes novel FLT3-targeted therapies, as well as efficient combination therapies for FLT3-mutated leukemia cells.
DOI: 10.1056/nejmoa041974
发表时间: 2005-01-20
影响因子: 158.5
作者:
Falini, B;Mecucci, C;Martelli, MF
通讯作者: Martelli, MF
DOI: 10.1016/j.leukres.2005.07.015
发表时间: 2006-06-01
期刊: LEUKEMIA RESEARCH
影响因子: 2.7
作者:
Inomata, M;Takahashi, S;Sasaki, T
通讯作者: Sasaki, T
DOI: 10.1128/mcb.13.10.6572
发表时间: 1993-10-01
影响因子: 5.3
作者:
DOSIL, M;WANG, SL;LEMISCHKA, IR
通讯作者: LEMISCHKA, IR
DOI: 10.1182/blood-2004-07-2942
发表时间: 2005-07-01
期刊: BLOOD
影响因子: 20.3
作者:
Choudhary, C;Schwäble, J;Serve, H
通讯作者: Serve, H
DOI: 10.1038/sj.leu.2404684
发表时间: 2007-06-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Juarez, J.;Dela Pena, A.;Bendall, L. J.
通讯作者: Bendall, L. J.